Statins reduce testicular and ocular VEGF: A potential compromise to microcirculation

Simple item page
dc.contributor.authorEkerbicer N.
dc.contributor.authorGurpinar T.
dc.contributor.authorSisman A.R.
dc.contributor.authorGuvendi G.
dc.contributor.authorCamsari U.M.
dc.contributor.authorUysal N.
dc.date.accessioned2024-07-22T08:09:42Z
dc.date.available2024-07-22T08:09:42Z
dc.date.issued2018
dc.description.abstractMicrocirculation has great importance in eye and testicular tissue and is necessary to have adequate and appropriate amount of angiogenesis. It is known that high levels of Vascular Endothelial Growth Factor (VEGF) trigger uncontrolled angiogenesis, whereas inadequate VEGF can lead to decreased tissue perfusion and oxygenation. The aim of this study was to investigate effects of VEGF in testicular and ocular tissues in both non-diabetic and diabetic rats treated by statin. Atorvastatin (10 mg/kg daily given by orally gavage) was administered for two weeks. Diabetes was induced by streptozotocin, (STZ, 45 mg/kg/ip) in diabetic group's rats. Two weeks later from STZ injection, atorvastatin treatment was initiated in diabetic group. VEGF levels were measured by using ELISA. The VEGF levels were decreased in vitrous, ocular and testicular tissues of all statin-administered rats. In diabetic group VEGF levels were found to be decreased in testicular tissue and increased in ocular tissues. Conclusion: Statin use decreased in VEGF levels of testicular and ocular tissues in diabetic and non-diabetic rats. Statin treatment (anti-VEGF effect) had a protective effect in the development of diabetic retinopathy, yet statins may have a negative impact on tissues that depend on microcirculation by reducing VEGF levels. Further research is needed for statins’ microcellular effects. © 2018 Elsevier Inc.
dc.identifier.DOI-ID10.1016/j.mvr.2018.04.006
dc.identifier.issn00262862
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/14932
dc.language.isoEnglish
dc.publisherAcademic Press Inc.
dc.subjectAngiogenesis Inhibitors
dc.subjectAnimals
dc.subjectAtorvastatin
dc.subjectDiabetes Mellitus, Experimental
dc.subjectDiabetic Retinopathy
dc.subjectDown-Regulation
dc.subjectEye
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitors
dc.subjectMale
dc.subjectMicrocirculation
dc.subjectNeovascularization, Pathologic
dc.subjectRats, Wistar
dc.subjectTestis
dc.subjectVascular Endothelial Growth Factor A
dc.subjectatorvastatin
dc.subjectvasculotropin
dc.subjectangiogenesis inhibitor
dc.subjectatorvastatin
dc.subjecthydroxymethylglutaryl coenzyme A reductase inhibitor
dc.subjectvascular endothelial growth factor A, rat
dc.subjectvasculotropin A
dc.subjectadverse outcome
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectArticle
dc.subjectcontrolled study
dc.subjectdiabetic retinopathy
dc.subjectdrug effect
dc.subjectenzyme linked immunosorbent assay
dc.subjecteye
dc.subjectmale
dc.subjectmicrocirculation
dc.subjectnonhuman
dc.subjectpriority journal
dc.subjectprotein determination
dc.subjectprotein localization
dc.subjectrat
dc.subjectstreptozotocin-induced diabetes mellitus
dc.subjecttestis
dc.subjecttissue level
dc.subjectanimal
dc.subjectcomplication
dc.subjectdiabetic retinopathy
dc.subjectdown regulation
dc.subjectdrug effect
dc.subjectexperimental diabetes mellitus
dc.subjecteye
dc.subjectmetabolism
dc.subjectmicrocirculation
dc.subjectneovascularization (pathology)
dc.subjectpathophysiology
dc.subjecttestis
dc.subjectvascularization
dc.subjectWistar rat
dc.titleStatins reduce testicular and ocular VEGF: A potential compromise to microcirculation
dc.typeArticle

Files

Collections

Scopus Koleksiyonu